Nephrocare Health Services reported a strong H1FY27, with revenue growing 23.6% YoY to Rs 585.2 crore and adjusted PAT climbing 34.7% to Rs 76.1 crore. The network expanded to 570 clinics, with international markets contributing 47% of revenue. While management exceeded growth targets, investors should monitor margin contraction linked to ongoing global expansion and new market ramp-ups.
Nephrocare Health Services Reports Strong H1 Growth
Revenue grew 23.6% to Rs 585.2 crore in H1FY27, with adjusted PAT reaching Rs 76.1 crore.
Reader Takeaway: Strong revenue and volume growth highlight aggressive expansion, but watch for margin pressure from new clinic ramp-ups.
What just happened
Nephrocare Health Services announced its H1FY27 results, showing significant top-line and bottom-line growth. Consolidated revenue for the first half reached Rs 585.2 crore, up 23.6% from the previous year. Adjusted PAT rose by 34.7% to Rs 76.1 crore. The company saw a 12.6% increase in total treatments, reaching 21.01 lakh, while Revenue Per Treatment (RPT) improved by 9.7% to Rs 2,785.
Why this matters
The company is aggressively scaling its footprint, now operating 570 clinics across six countries. International operations have become a primary growth engine, contributing approximately 47% of total revenue. Management’s ability to outperform their 15–20% guidance indicates strong demand for their dialysis services both in India and overseas.
Strategic Developments
Expansion remains a core focus. The firm recently entered Kazakhstan by acquiring two clinics and added 10 clinics in the Philippines. In the Middle East, the Riyadh clinic is operational, and home dialysis services have launched in Saudi Arabia. The company is currently shortlisted among 12 providers for the Saudi Ministry of Health tender, a key milestone for future regional growth.
Risks to watch
Investors should note a contraction in adjusted EBITDA margins, which dipped to 23.0% in H1FY27 compared to 24.6% in the same period last year. Management attributed this to increased investments in clinical talent and the costs associated with scaling operations in new geographies. The profitability of these new clinics remains a sensitive area as they move through the initial ramp-up phase.
What to track next
Future performance will depend on the outcome of the Saudi Arabia government tender and the speed at which newly acquired international assets achieve operational break-even. Additionally, the success of clinical initiatives like the Peritoneal Dialysis pilot in Punjab will be key to long-term service diversification.